GSK announces CHMP of the EMA recommended expanding approval of Jemperli
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...
GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
GSK’s ViiV Healthcare says the CHMP of EMA issued positive opinion for Vocabria
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...
GSK, China’s Zhifei Extend Shingles Shot Collaboration to 2034
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
FiercePharma11 天
GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal
Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...
GSK's Cancer Drug Jemperli Nears EU Marketing Expansion -- 2nd Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...